Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016)

Cecilia G Carvalhaes; Michael D Huband; Harald H Reinhart; Robert K Flamm; Helio S Sader

doi:10.1128/AAC.02262-18

Back

Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016)

Journal article

Open access

Peer reviewed

Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016)

Cecilia G Carvalhaes, Michael D Huband, Harald H Reinhart, Robert K Flamm and Helio S Sader

Antimicrobial agents and chemotherapy, Vol.63(3), e02262-18

03/2019

DOI: 10.1128/AAC.02262-18

PMCID: PMC6395890

PMID: 30617092

Files and links (1)

url

https://doi.org/10.1128/AAC.02262-18View

Published (Version of record) Open Access

Abstract

Omadacycline is a derivative of minocycline and the first agent of the aminomethylcycline class. A total of 3,282 organisms (1 per patient) were consecutively collected from patients hospitalized in China (including Hong Kong) and Taiwan. Susceptibility testing was performed by broth microdilution methods in a central laboratory (JMI Laboratories). The collection included Gram-positive and Gram-negative organisms from patients with pneumonia, bloodstream, skin, community-acquired respiratory, and other infections. Omadacycline was very potent against ( = 689; MIC , 0.12/0.25 mg/liter), including methicillin-resistant (MRSA; = 299; MIC , 0.12/0.5 mg/liter), and had similar activity across geographic regions. Omadacycline was very active against (highest MIC, 0.25 mg/liter), β-hemolytic streptococci (highest MIC, 1 mg/liter), viridans group streptococci (highest MIC, 0.25 mg/liter), and spp. (highest MIC, 0.5 mg/liter) from all geographic regions. Overall, 53.8% of isolates were penicillin resistant (penicillin MIC, ≥2 mg/liter) and 10.7% of enterococci (21.2% among isolates) were vancomycin resistant. Omadacycline was active against (MIC , 0.5/1 mg/liter) regardless of β-lactamase production and was active against (MIC , ≤0.12/0.25 mg/liter). Against , omadacycline was most active against (MIC , 1/2 mg/liter), (MIC , 1/4 mg/liter), and (MIC , 2/4 mg/liter). Omadacycline had potent activity against Gram-positive and Gram-negative pathogens isolated from China and Taiwan and retained activity against problem pathogens, such as MRSA, vancomycin-resistant enterococci (VRE), penicillin-resistant (PRSPN), and extended-spectrum β-lactamase-producing The observed MIC profile in Chinese isolates was very similar to that seen in the U.S. and European surveillance studies.

China

Hong Kong

Taiwan

Anti-Bacterial Agents - therapeutic use

Bacterial Infections - drug therapy

Bacterial Infections - microbiology

Community-Acquired Infections - drug therapy

Community-Acquired Infections - microbiology

Enterobacteriaceae - drug effects

Enterobacteriaceae - isolation & purification

Enterococcus faecium - drug effects

Enterococcus faecium - isolation & purification

Haemophilus influenzae - drug effects

Haemophilus influenzae - isolation & purification

Humans

Microbial Sensitivity Tests

Soft Tissue Infections - drug therapy

Soft Tissue Infections - microbiology

Staphylococcal Skin Infections - drug therapy

Staphylococcus aureus - drug effects

Staphylococcus aureus - isolation & purification

Streptococcus pneumoniae - drug effects

Streptococcus pneumoniae - isolation & purification

Tetracyclines - therapeutic use

Details

Title: Subtitle: Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016)
Creators: Cecilia G Carvalhaes - JMI Laboratories
Michael D Huband - JMI Laboratories
Harald H Reinhart - Zai Lab (Shanghai) Co., Ltd., Pudong, Shanghai, China.
Robert K Flamm - JMI Laboratories
Helio S Sader - JMI Laboratories
Resource Type: Journal article
Publication Details: Antimicrobial agents and chemotherapy, Vol.63(3), e02262-18
DOI: 10.1128/AAC.02262-18
PMID: 30617092
PMCID: PMC6395890
ISSN: 0066-4804
eISSN: 1098-6596
Grant note: name: Zai Laboratories
Language: English
Date published: 03/2019
Academic Unit: Pathology
Record Identifier: 9984185177902771

Metrics

20 Record Views

25 Times Cited - Web of Science

See more details